Obesity drug CagriSema misses goal of 25% body weight reduction
Novo Nordisk, one of Europe’s largest companies, lost more than a quarter of its value on Friday after its latest obesity drug missed the drugmaker’s goal for an average of 25 per cent weight loss. CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of Mounjaro, a rival treatment from Eli Lilly.
Novo Nordisk had hoped its “next generation” weight-loss drug could lead the field, after its shares had struggled to keep pace with Eli Lilly and it suffered a setback from disappointing results for an experimental weight-loss pill in September.“CagriSema is really important for us,” chief executive Lars Fruergaard Jørgensen told the Financial Times in November. “It’s a next-generation product and it has the potential to be best in class.” Patients receiving Mounjaro lost an average of 22.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Anti-obesity drugs increase food waste in some usersTaking anti-obesity drugs has led some U.S. adults to throw away more food than they tossed before starting the medications, a new study has found.
Read more »
Obesity epidemic sees undertakers report injuries from the weight of heavy coffinsBritain’s undertakers are reportedly struggling with the weight of coffins amid the ever-worsening obesity epidemic.
Read more »
Discovery of leptin-responsive neurons offers new hope for obesity treatmentObesity affects a staggering 40 percent of adults and 20 percent of children in the United States. While some new popular therapies are helping to tackle the epidemic of obesity, there is still so much that researchers do not understand about the brain-body connection that regulates appetite.
Read more »
Anti-obesity medications could help treat alcohol use disordersLosing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open.
Read more »
Geneva University Study Reveals Negative Sentiments on Obesity in Social MediaA study by Geneva University Hospitals (HUG) and the University of Geneva (UNIGE) analyzing tweets from April 2019 to December 2022 found that most convey negative sentiments about overweight. The positions of influential figures significantly shape public opinion, highlighting discrimination and the role of social networks in spreading criticism.
Read more »
Racial and Ethnic Disparities in Obesity Medication UseA new study suggests that Asians, non-Hispanic Blacks, and Hispanics are less likely to use obesity-management medications compared to whites, even after accounting for factors like income, education, insurance, and health need. This disparity calls for further research to understand the underlying barriers faced by racial and ethnic minority groups in accessing obesity treatment.
Read more »